Lin Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lin Yan has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Fenqin Zhao
State Key Laboratory of Antiviral Drugs, School of Pharmacy, Henan University, N. Jinming Ave., Kaifeng, Henan 475004, China
9 shared publicationsBingxin Wang
State key Laboratory of Antiviral Drugs, School of Pharmacy, Henan University, Kaifeng, Henan, 475004, China
6 shared publicationsJiahao Du
State Key Laboratory of Antiviral Drugs, School of Pharmacy, Henan University, N. Jinming Ave., Kaifeng, Henan 475004, China
6 shared publicationsYu Wang
State Key Laboratory of Antiviral Drugs, School of Pharmacy, Henan University, N. Jinming Ave., Kaifeng, Henan 475004, China
6 shared publicationsNing Guo
State Key Laboratory of Antiviral Drugs, School of Pharmacy, Henan University, N. Jinming Ave., Kaifeng, Henan 475004, China; Department of Pharmacy, Huaihe Hospital of Henan University, Kaifeng, Henan 475004, China
5 shared publicationsWeibin Zhai
State Key Laboratory of Antiviral Drugs, School of Pharmacy, Henan University, N. Jinming Ave., Kaifeng, Henan 475004, China
5 shared publications
Latest Publications
- 29 May 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 180, 110058
Structure-guided discovery of phenyl-carbamates as novel dual TRPV1 antagonists/FAAH inhibitors
- 29 May 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 180, 110058
Structure-guided discovery of phenyl-carbamates as novel dual TRPV1 antagonists/FAAH inhibitors
- 7 April 2026
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 18 (15) , 3216-3223
Rational design of environment-sensitive fluorescent probes for butyrylcholinesterase and their application in biological imaging
Butyrylcholinesterase (BChE) is closely associated with Alzheimer's disease (AD), with its expression significantly elevated in the brains of AD patients. This enzyme has emerged as a potential biomarker for monitoring AD progression. Therefore, developing a reliable chemical tool to detect BChE both in vitro and in vivo is of considerable interest. In this study, we rationally designed a series of environmentally sensitive fluorescent probes targeting BChE, based on a highly potent, selective, and reversible BChE inhibitor. Among these, the most promising probe ESP4 demonstrated an ultrafast response to BChE with exceptional sensitivity (LOD = 1.81 nM), enabling high-precision detection of BChE. Additionally, ESP4 maintained robust inhibitory activity against BChE in the low nanomolar range (IC50 = 71.78 ± 1.90 nM). Notably, ESP4 exhibited excellent selectivity for BChE, showing no interference from other biological species, including acetylcholinesterase (AChE). The probe also accurately measured the IC50 of tacrine (7.83 nM), a standard BChE inhibitor, demonstrating its reliability in evaluating BChE inhibition. Due to its high sensitivity, rapid response, and superior selectivity, ESP4 enabled real-time imaging of BChE in biological systems such as cells, zebrafish, and AD mouse models. Collectively, these findings highlighted ESP4 as a valuable tool for BChE detection, contributing to a deeper understanding of the physiological role of BChE in health and disease.
- 7 April 2026
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 18 (15) , 3216-3223
Rational design of environment-sensitive fluorescent probes for butyrylcholinesterase and their application in biological imaging
Butyrylcholinesterase (BChE) is closely associated with Alzheimer's disease (AD), with its expression significantly elevated in the brains of AD patients. This enzyme has emerged as a potential biomarker for monitoring AD progression. Therefore, developing a reliable chemical tool to detect BChE both in vitro and in vivo is of considerable interest. In this study, we rationally designed a series of environmentally sensitive fluorescent probes targeting BChE, based on a highly potent, selective, and reversible BChE inhibitor. Among these, the most promising probe ESP4 demonstrated an ultrafast response to BChE with exceptional sensitivity (LOD = 1.81 nM), enabling high-precision detection of BChE. Additionally, ESP4 maintained robust inhibitory activity against BChE in the low nanomolar range (IC50 = 71.78 ± 1.90 nM). Notably, ESP4 exhibited excellent selectivity for BChE, showing no interference from other biological species, including acetylcholinesterase (AChE). The probe also accurately measured the IC50 of tacrine (7.83 nM), a standard BChE inhibitor, demonstrating its reliability in evaluating BChE inhibition. Due to its high sensitivity, rapid response, and superior selectivity, ESP4 enabled real-time imaging of BChE in biological systems such as cells, zebrafish, and AD mouse models. Collectively, these findings highlighted ESP4 as a valuable tool for BChE detection, contributing to a deeper understanding of the physiological role of BChE in health and disease.
- 13 March 2026
- Published by Elsevier in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
- Vol. 356, 127729
A selective near-infrared fluorescent probe for detecting hydrogen peroxide in Alzheimer's disease
- 13 March 2026
- Published by Elsevier in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
- Vol. 356, 127729
A selective near-infrared fluorescent probe for detecting hydrogen peroxide in Alzheimer's disease
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (7) , 3323-3330
Rational design of an environment-sensitive fluorescent probe for monitoring butyrylcholinesterase activity and its application in Alzheimer's disease
LY36 integrates selective BChE inhibition with environment-sensitive fluorescence for real-time visualization of Alzheimer's pathology in biological models.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 17 (7) , 3323-3330
Rational design of an environment-sensitive fluorescent probe for monitoring butyrylcholinesterase activity and its application in Alzheimer's disease
LY36 integrates selective BChE inhibition with environment-sensitive fluorescence for real-time visualization of Alzheimer's pathology in biological models.
- 18 April 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 292, 117656
Design, synthesis and biological activity of novel pyrimidine piperazine ureas as μ-opioid and TRPV1 dual-target ligands for pain management
- 18 April 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 292, 117656
Design, synthesis and biological activity of novel pyrimidine piperazine ureas as μ-opioid and TRPV1 dual-target ligands for pain management
- 2 February 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 267, 116208
Novel dual-target FAAH and TRPV1 ligands as potential pharmacotherapeutics for pain management
- 2 February 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 267, 116208
Novel dual-target FAAH and TRPV1 ligands as potential pharmacotherapeutics for pain management
- 28 October 2023
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 148 (24) , 6325-6333
Design, synthesis and biological evaluation of small molecule fluorescent probes targeting EGFR for tumor detection and treatment
The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that plays a crucial role in cell differentiation and tumor progression, and its overexpression is closely associated with the development and metastasis of multiple cancers. The development of a fluorescent probe capable of targeting EGFR while simultaneously integrating diagnostic and therapeutic functions could have a profound impact on the treatment of related cancers. In this study, we developed a series of EGFR-targeting probes that consisted of an environment-sensitive 1,8-naphthalimide fluorophore, a linker unit and a targeting unit (gefitinib), using a coupling strategy. The synthesized probes were first evaluated for their spectroscopic properties and cytotoxicities against different cell lines, which were selected based on their intrinsic EGFR expression levels. Remarkably, among the probes tested, GP1 showed outstanding environmental sensitivity and exhibited a specific response to tumor cells that overexpress EGFR. Furthermore, the representative probe GP1 was evaluated for its EGFR-specific targeting ability in live-cell fluorescence imaging and in vivo xenograft imaging, as well as its in vivo anti-tumor activity. The results showed that the probe GP1 had excellent EGFR-specific targeting ability, exhibited competitive replacement behavior towards the EGFR inhibitor gefitinib, and demonstrated potent anti-tumor effects in a CT-26 tumor-bearing mouse model. Overall, as a turn-on EGFR targeting fluorescent ligand, GP1 holds immense promise as a valuable tool for tumor detection and treatment.
- 28 October 2023
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 148 (24) , 6325-6333
Design, synthesis and biological evaluation of small molecule fluorescent probes targeting EGFR for tumor detection and treatment
The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that plays a crucial role in cell differentiation and tumor progression, and its overexpression is closely associated with the development and metastasis of multiple cancers. The development of a fluorescent probe capable of targeting EGFR while simultaneously integrating diagnostic and therapeutic functions could have a profound impact on the treatment of related cancers. In this study, we developed a series of EGFR-targeting probes that consisted of an environment-sensitive 1,8-naphthalimide fluorophore, a linker unit and a targeting unit (gefitinib), using a coupling strategy. The synthesized probes were first evaluated for their spectroscopic properties and cytotoxicities against different cell lines, which were selected based on their intrinsic EGFR expression levels. Remarkably, among the probes tested, GP1 showed outstanding environmental sensitivity and exhibited a specific response to tumor cells that overexpress EGFR. Furthermore, the representative probe GP1 was evaluated for its EGFR-specific targeting ability in live-cell fluorescence imaging and in vivo xenograft imaging, as well as its in vivo anti-tumor activity. The results showed that the probe GP1 had excellent EGFR-specific targeting ability, exhibited competitive replacement behavior towards the EGFR inhibitor gefitinib, and demonstrated potent anti-tumor effects in a CT-26 tumor-bearing mouse model. Overall, as a turn-on EGFR targeting fluorescent ligand, GP1 holds immense promise as a valuable tool for tumor detection and treatment.
- 10 October 2023
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1281, 341900
Rational design synthesis and evaluation of a novel near-infrared fluorescent probe for selective imaging of amyloid-β aggregates in Alzheimer's disease
- 10 October 2023
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1281, 341900
Rational design synthesis and evaluation of a novel near-infrared fluorescent probe for selective imaging of amyloid-β aggregates in Alzheimer's disease
- 23 December 2022
- Published by Elsevier in Bioorganic Chemistry
- Vol. 131, 106335
Novel dual-target μ‑opioid and TRPV1 ligands as potential pharmacotherapeutics for pain management
- 23 December 2022
- Published by Elsevier in Bioorganic Chemistry
- Vol. 131, 106335
Novel dual-target μ‑opioid and TRPV1 ligands as potential pharmacotherapeutics for pain management